Cost-effectiveness of sugemalimab plus chemotherapy as first-line therapy in advanced gastric cancer and gastroesophageal junction cancer.

ABSTRACT:

Background

The GEMSTONE-303 trial demonstrated that sugemalimab combined with capecitabine and oxaliplatin (CAPOX) improved survival benefit in patients with advanced gastric/gastroesophageal junction cancer (GC/GEJC) and a programmed death-ligand 1 (PD-L1) combined positive score (CPS) ≥5. However, its cost-effectiveness in China remains unassessed.

Methods

A partitioned survival model was developed from the Chinese healthcare payer perspective using data from the GEMSTONE-303 trial. Costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs) were evaluated over a 10-year horizon. Sensitivity analyses assessed model uncertainty, while subgroup and scenario analyses examined the impact of PD-L1 expression, drug pricing, and patient assistanc

SUBMITTER: Zhu J 

PROVIDER: S-EPMC12697266 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature